Fig. 1From: Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancerStudy design: open-label, nonblinded, multicenter, Phase II trialBack to article page